ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Stress, Hypothalamic-Pituitary-Adrenal (HPA) Dysfunction, and Relapse in Alcoholism

This study is currently recruiting participants.
Verified by University of Texas Southwestern Medical Center, August 2008

Sponsors and Collaborators: University of Texas Southwestern Medical Center
Dallas VA Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by: University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT00744588
  Purpose

This proposal is part of the INIA Stress Consortium. This study will

  1. explore the contributions of lifetime trauma, recent stress, and alcohol use on stress-hormone axis disruption in treatment seeking, one-month abstinent, alcohol-dependent subjects
  2. assess the combined contributions of stress-hormone axis disruption and episodic stress on the risk of prospective drinking following treatment
  3. determine the role of neurosteroids in alcohol use.

Condition
Alcohol Dependence

MedlinePlus related topics:   Alcohol Consumption    Alcoholism    Injuries    Stress    Wounds   

Drug Information available for:   Hydrocortisone    Cortisol 21-phosphate    Cortisol succinate    Hydrocortamate    Hydrocortisone 21-sodium succinate    Hydrocortisone acetate    Hydrocortisone cypionate    Hydrocortisone hemisuccinate    Proctofoam-HC    Cosyntropin    Corticotropin    Epinephrine    Epinephrine bitartrate    Ethanol    Corticotropin-releasing hormone   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Case-Only, Cross-Sectional
Official Title:   Stress, HPA Dysfunction, and Relapse in Alcoholism

Further study details as provided by University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • Examine the contributions of previous trauma, recent stress, and chronic alcohol use to the stress-hormone axis reactivity in one-month abstinent alcohol-dependent subjects. [ Time Frame: one month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess the ability of stress-hormone axis reactivity and ongoing stress to predict subsequent drinking behavior following treatment discharge. [ Time Frame: Six months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

serum plasma whole blood urine


Estimated Enrollment:   100
Study Start Date:   August 2007
Estimated Study Completion Date:   June 2012
Estimated Primary Completion Date:   December 2011 (Final data collection date for primary outcome measure)

Groups/Cohorts
alcohol dependence
Alcohol-dependent subjects currently being treated in an inpatient treatment facility.

Detailed Description:

The hypothalamic-pituitary-adrenal (HPA) system is suggested as a key biologic link in stress-induced relapse. The HPA axis provides a regulatory feedback network between the brain and the body's behavioral and physiologic responses to stress, recovery, and adaptation. Both trauma and chronic alcohol use produce persistent disturbances in the HPA response to stress. The chronic use of alcohol may also impair the stress-induced release of neurosteroids, compounds that directly modulate central nervous system activity. Thus, altered cortisol and neurosteroid responsiveness during abstinence may impair the central nervous system's ability to mount an appropriate response to environmental stressors, heightening the probability of relapse. However, the relationship between stress, relapse, and HPA axis disturbances remains tentative. In the proposed study, the investigators will assess the contribution of trauma, stress, and alcohol use upon pituitary-adrenocortical functioning in alcohol dependence. The relative contribution of adrenocortical disruption and episodic stress to prospective drinking behaviors will then be determined.

Hypothesis: We hypothesize (1) that lifetime trauma, recent stress, and chronic alcohol use will additively contribute to HPA axis disruption, (2) alterations in glucocorticoid and neurosteroid release as well as episodic stress will predict a return to drinking.

Methods: One hundred treatment-seeking, one-month abstinent, alcohol-dependent subjects will be studied. Standardized assessments will be used to assess childhood and adult trauma as well as recent (six months) stress. Pituitary-adrenal (including ACTH, cortisol, and neurosteroids) responses to both neuroendocrine [ovine corticotropin releasing hormone (oCRH), cosyntropin, and dexamethasone] and experiential (public speaking) challenges will be measured. Drinking behavior and episodic stress will be prospectively assessed for six months following neuroendocrine assessment.

Significance: If our hypotheses are supported, a definitive connection between previous trauma, biological stress response mechanisms, and ongoing stress upon prospective drinking behavior will be demonstrated. The identification of a specific biologic mechanism that underlies this association will provide a fertile framework for the development of targeted pharmacological interventions to decrease relapse in this vulnerable population. In addition, elucidating the concurrent contributions of stress-response biologic systems and externals stressors will provide the therapist and patient with a constellation of specific risk factors for focused treatment.

  Eligibility
Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample

Study Population

Inpatient treatment facility for substance use disorders.


Criteria

Inclusion Criteria:

  • Diagnosis of alcohol dependence

Exclusion Criteria:

  • Medical or psychiatric disorders that may effect stress-hormone axis functioning.
  • Medications that may effect stress-hormone axis functioning.
  • English speaking.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00744588

Contacts
Contact: Michael F Lay     214 6456989     michael.lay@utsouthwestern.edu    
Contact: Kirsten Gilbert     214 6455988     kirsten.gilbert@utsouthwestern.edu    

Locations
United States, Texas
UT Southwestern Medical Center at Dallas     Recruiting
      Dallas, Texas, United States, 75390-8564
      Contact: Bryon Adinoff, MD     214-645-6975     bryon.adinoff@utsouthwestern.edu    
      Contact: Michael Lay, BA     214-675-6989 ext 284     michael.lay@utsouthwestern.edu    
      Principal Investigator: Bryon Adinoff, MD            

Sponsors and Collaborators
University of Texas Southwestern Medical Center
Dallas VA Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators
Principal Investigator:     Bryon Adinoff, MD     UT Southwestern Medical Center at Dallas and VA North Texas Health Care System    
  More Information


Home page for principal investigator  This link exits the ClinicalTrials.gov site
 

Responsible Party:   University of Texas Southwestern Medical Center at Dallas ( Bryon Adinoff, MD, Professor )
Study ID Numbers:   AA016668, U01-AA016668-02
First Received:   June 19, 2008
Last Updated:   August 29, 2008
ClinicalTrials.gov Identifier:   NCT00744588
Health Authority:   United States: Institutional Review Board

Keywords provided by University of Texas Southwestern Medical Center:
substance abuse  
alcohol dependence  
hypothalamic-pituitary-adrenal (HPA) system  
cosyntropin  
corticotropin-releasing Hormone (CRH)  
pituitary-adrenal system  
stress
trauma
neurosteroids
cortisol
relapse

Study placed in the following topic categories:
Hydrocortisone
Corticotropin-Releasing Hormone
Cortisol succinate
Wounds and Injuries
Stress
Disorders of Environmental Origin
Cosyntropin
Adrenocorticotropic Hormone
Recurrence
Mental Disorders
Alcoholism
Substance-Related Disorders
Alcohol-Related Disorders
Hydrocortisone acetate
Epinephrine
Ethanol

Additional relevant MeSH terms:
Disease Attributes
Pathologic Processes
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 24, 2008




Links to all studies - primarily for crawlers